Basic Information
| LncRNA/CircRNA Name | TBILA |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP |
| Sample | non small cell lung cancer tissues, cell lines (A549 and H226) |
| Expression Pattern | up-regulated |
| Function Description | We observed that one of the most prominent hits, TGF?-induced lncRNA (TBILA), promoted NSCLC progression and was upregulated in tumor tissues. Upregulated TBILA promotes human germinal center-associated lymphoma (HGAL) expression by binding to the Smad transcription factor complex, thereby enhancing RhoA activation. In addition, TBILA induces the S100A7-c-Jun activation domain-binding protein 1 (JAB1) pathway by binding to nuclear S100A7 and enhances pro-survival pathways in NSCLC. Flowcytometric analyses showed that TBILA overexpression rendered NSCLCcells more resistant to cisplatin-induced apoptosis after 24 h of cisplatintreatment. The number of TBILA-overexpressing clones that passed throughthe transwell chambers was significantly higher than the number ofmock-vector control cells that passed through the chambers. |
| Pubmed ID | 29908210 |
| Year | 2018 |
| Title | The TGF?-induced lncRNA TBILA Promotes Non-Small Cell Lung Cancer Progression in Vitro and in Vivo via Cis-Regulating HGAL and Activating S100A7/JAB1 Signaling |
External Links
| Links for TBILA | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |